Blog
RSS FeedPosted by Michael Wonder on 29 May 2024
Trastuzumab deruxtecan for the treatment of patients with advanced HER2 mutation positive non-small-cell lung cancer after platinum-based chemotherapy
29 May 2024 - NICE is unable to make a recommendation on the use of trastuzumab deruxtecan (Enhertu) for the treatment ...
Posted by Michael Wonder on 28 May 2024
David Seymour’s special envoy in medicines is dumping his drug company investments
28 May 2024 - Act MP Todd Stephenson is selling his investments in drug companies while labelling as “outrageous” claims ...
Posted by Michael Wonder on 28 May 2024
The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study
27 May 2024 - The Patented Medicine Prices Review Board (PMPRB), the agency that regulates the prices of patented medicines in ...
Posted by Michael Wonder on 25 May 2024
Issues, challenges and opportunities for economic evaluations of orphan drugs in rare diseases: an umbrella review
25 May 2024 - There are significant challenges when obtaining clinical and economic evidence for health technology assessments of rare diseases. ...
Posted by Michael Wonder on 25 May 2024
Moving forward on Pharmacare for Canadians
24 May 2024 - Pharmacare legislation includes universal access to contraception and diabetes medications. ...
Posted by Michael Wonder on 24 May 2024
NICE and NHS England announce plan to enable innovative tech to be adopted quicker
23 May 2024 - NHS patients in England will benefit from faster access to the most innovative and cutting-edge medical technologies ...
Posted by Michael Wonder on 24 May 2024
Bausch Health announces additional public drug plan listings for Uceris (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults
23 May 2024 - Bausch Health today announced additional Canadian public drug plan listings for Uceris (budesonide) aerosol foam to ...
Posted by Michael Wonder on 23 May 2024
Historical archive of the Schedule of Pharmaceutical Benefits (1951-2002)
23 May 2024 - The Department of Health and Aged Care has completed the digitisation, and is making available for public ...
Posted by Michael Wonder on 23 May 2024
Setmelanotide acetate for the treatment of patients with obesity and hyperphagia in Bardet-Biedl syndrome (final guidance)
22 May 2024 - NICE has published final evidence-based recommendations on the use of setmelanotide acetate (Imcivree) for treating obesity ...
Posted by Michael Wonder on 23 May 2024
PMPRB report examines availability and pricing of new medicines
22 May 2024 - The Patented Medicine Prices Review Board (PMPRB) published the eighth edition of its annual Meds Entry Watch ...
Posted by Michael Wonder on 22 May 2024
Sirolimus for the treatment of patients with facial angiofibroma caused by tuberous sclerosis complex
22 May 2024 - NICE is unable to make a recommendation on the use of sirolimus (Hyftor) for the treatment of ...
Posted by Michael Wonder on 22 May 2024
The National Advisory Committee on Immunization recommends Beyfortus to protect all infants against RSV
21 May 2024 - The National Advisory Committee on Immunization issued a recommendation for Beyfortus (nirsevimab) to be used for the ...
Posted by Michael Wonder on 22 May 2024
$43.9 million to boost fight against HIV infection
21 May 2024 - The Albanese Government is investing $43.9 million to put Australia on track to eliminate transmission of ...
Posted by Michael Wonder on 19 May 2024
Doctors say PHARMAC too slow to act over hormone replacement therapy patch shortage
18 May 2024 - The shortage of hormone replacement therapy patches is getting worse, and PHARMAC has been too slow ...
Posted by Michael Wonder on 17 May 2024
Efanesoctocog alfa for the treatment and prevention of bleeding episodes in patients with haemophilia A
17 May 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...